A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 0-9 |

Cifo s.p.a_

ELENCO DELLE PRIME 15 AZIENDE FRANCESI NEL
SETTORE BIOTECH

REGIONE ILE DE FRANCE
1_
LFB – Sede centrale
Laboratoire Français du Fractionnement et des Biotechnologies
3 avenue des Tropiques - BP 305 – Les Ulis
91958 Courtaboeuf Cedex – France
Telefono :
0033 1 69 82 70 10
0033 1 69 07 19 03
communication@lfb.fr
Sito Web :
www.lfb.fr

Presenza in Francia
LFB Biomédicaments (Lille)
Sito produttivo a Les Ulis (91000)
Presenza all’estero
Filiale in Brasile, Germania e Regno Unito

Dati principali 2008

Responsabili
Direttore :
Direttore Affari Generali

Presentazione e/o prodotti
Leader in France in the field of plasma-derived medicinal products, 6th player wordwide, LFB Group is also one of the leading European companies for the development of monoclonal antibodies and new-generation proteins based on biotechnologies.
LFB is dedicated to developing, manufacturing and marketing medicinal products for serious
, and often rare diseases . R&D is key to tehe strategy of LFB Group. With a 2008 budget
amounting to nearly 20% of the turnover, research projects concern both a number of
developments in the field of plasma proteins,and the marketing of products based on
biotechnologies, in essential therapeutic areas such as immunology, hemostasis, intensive
care and oncology.

44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it
2_
ETHYPHARM S.A –Sede centrale
194 bureaux de la colline, Bat D
92 213 Saint-Cloud
France
Telefono :
0033 1 41 12 17 20
0033 1 41 12 17 30
: contact@ethypharm.com
Sito web :
www.ethypharm.com

Presenza in Francia :
+ 1 laboratorio a Chateauneuf en Thymerais - (28170)
+ 2 siti produttivi (Houdan –Le Grand Quevilly)- (76120)

Responsabili
Direttori Generali:

Dati principali 2008

Presenza all’estero
Ethypharm North America -200 boul. Armand-Frappier, Laval, Québec, (Canada) H7V 4A6
touam.hafid@ethypharmusa.com
Ethypharm USA Inc. -1500 Market Street, 12th Floor, East Tower - Philadelphia, PA, 19102, USA
touam.hafid@ethypharmusa.com
Ethypharm China - C-D, 11 Floor, 9 Joy Tower, No.9, Zhen Ning Road, 200051 -Shanghai, China -
hao.xiaofan@ethypharm.com.cn
Ethypharm India - Fortune 200 C1, 2nd, Bandra Kurla Complex, Bandra East, Mumbai – 400 051 -
vksingh@ethypharmindia.com
Ethypharm JapanShiodome Shibarikyu Bldg. 21F, 1-2-3 Kaigan, Minato-ku, Tokyo 105-0022, Japan -
ukai_keiko@ethypharm.co.jp

Prodotti
Tramadol, Oxycodone, Ketoprofen Omeprazole, Morphine Sulfate, which totalizes more than 80% market
shares in France for immediate or delayed release oral forms.
Buprenorphine - The Company is also dedicated to the development of modified release oral forms of products
destined for treatment of central nervous system diseases for the treatment of opiate addiction, and Mirtazapine
for depression.
Ethypharm has also concentrated upon formulations and key developments in the cardiovascular field. Over 10
products are presently marketed on a world-wide scale, such as Diltiazem, ISMN or Fenofibrate.
Ethypharm recently developed Esomeprazole, a product that logically comes just after the success of the launch
of its Omeprazole.

44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it
3_
HYBRIGENICS- Sede
3-5 impasse Reille
75014 Paris
France
Telefono :
0033 1 58 10 38 00
0033 11 58 10 38 49
contact@hybrigenics.com
Sito web :
www.hybrigenics.com

Dati principali 2008
Totale investimenti dalla data di creazione –Equity fund - (milioni di €) Totale sovvenzioni ricevute (milioni di €)
Responsabili
Direttore :

Presenza all’estero
USA/Canada - Bioteam Boston +1 617 583 1350
Japon - CTC Laboratory System +81 (0)3 3419 9347
Presentazione e/o prodotti
Hybrigenics was founded in 1997 as a spin-off of Pasteur Institute to develop and industrialize
a high throughput platform to detect and identify protein interactions using the two-hybrid
technology in yeast (Yeast Two-Hybrid, Y2H).
Hybrigenics is a biotechnology and pharmaceutical company focusing its internal R&D programs on innovative
target and therapeutics against cancer and commercializing its high throughput technology and bioinformatics platforms to identify, validate and inhibit protein interactions. Hybrigenics’ most advanced development program is based on inecalcitol, a vitamin D analogue, for prostate cancer in combination with current reference treatments, for improved efficacy and better tolerance. Hybrigenics’ research program explores the role of Ubiquitin-Specific Proteases (USPs) in the degradation of onco-proteins, and the use of proprietary USP inhibitors against various cancer types. Hybrigenics offers to researchers from all life sciences an access to its ISO 9001-certified Yeast-Two Hybrid (Y2H) high throughput screening platform, to its sophisticated bioinformatics set of tools and extensive database, and to its chemical library and high throughput small molecule screening platform, as fee-for-service Hybrigenics is organized in two operational units: Hybrigenics Pharma for the internal R&D programs and Hybrigenics Services for the commercial business, coordinated with economies of scale by a common corporate, 44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it financial and administrative management. The core link among all Hybrigenics activities is trust in science for life.

_ 4
CEREP- Sede principale
155 Boulevard Haussmann
75008 Paris
France
Telefono :
0033 1 45 64 44 60
0033 1 45 64 44 64
sales@cerep.fr
www.cerep.fr

Presenza in Francia :
+ 1 stabilimento a Poitiers (86000)

Dati principali 2008
Totale investimenti dalla data di creazione –Equity fund - (milioni di €) Totale sovvenzioni ricevute (milioni di €)
Responsabili
Direttore Thierry
Direttore scientifico Olivier

Presenza all’estero
Redmond, WA (USA), Sales office in Tokyo (Japan)

Presentazione
Cerep offers preclinical drug discovery services for in vitro pharmacology, in vitro ADME-Tox & in vivo pharmacokinetics, and provides solutions allowing faster and cost-effective drug discovery by identifying at early stages the most promising drug candidates as wel as eliminating those compounds likely to fail in development. Cerep has developed unique know-how based on technologies of in vitro screening and of profiling using its proprietary database BioPrint®, which allows the modeling of clinical effects of drug candidates from their molecular properties. The strength of our services also originates from our in-house production of biological material or from established partnerships with renowned reagents providers (such as PerkinElmer). Cerep’s technologies benefit to more than 460 pharmaceutical and biotechnological companies worldwide including most of the top pharmaceutical firms. Cerep’s next objective is to open satellite laboratories, closer to where compounds are synthesized and drug candidates optimized, thus further decreasing turnaround time for data Bureau de Paris 44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it generation and delivery to discovery teams. The success of this endeavour can only be
achieved through the provision of consistent high quality data – reason for Cerep’s
permanence – wherever the screening is performed.

5 _
BIOALLIANCE PHARMA
49 bis Bd du Général Martial Val
75015 Paris

Telefono :
0033 1 45 58 76 00
0033 1 45 58 08 81
bioalliance@bioalliancepharma.com
Sito Web :
www.bioalliancepharma.com

Dati principali 2008
Totale investimenti dalla data di creazione –Equity fund - (milioni di €) 104 Totale sovvenzioni ricevute (milioni di €) 1,5
Responsabili
Presidente :
Direttore generale


Presentazione e/o prodotti
Development of novel approaches for treating HIV and cancer. 44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it
6 _
CELLECTIS
102 avenue Gaston Roussel
93230 Romainville

Telefono :
0033 1 41 83 99 00
0033 1 41 83 99 03
mail@cellectis.com
Sito Web :
www.cellectis.com

Dati principali 2008
Totale investimenti dalla data di creazione –Equity fund - (milioni di €) 42,2 Totale sovvenzioni ricevute (milioni di €)
Responsabili
Direttore :


Prodotti
Cellectis Sa is a word leader in genome engineering. The company specializes in the
development and production of meganucleases (DNA scissors) for in vivo genome surgery.
Cellectis products are programmed to induce unique, site-directed, double-strand
DNAbreaks in a living cell and can be used for a wide range of therapeutic and
biotechnological applications.

Bureau de Paris
44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it
7 _
EXONHIT THERAPEUTICS HYBRIGENICS
65 boulevard Masséna
75013 Paris

Telefono :
0033 1 53 94 77 00
0033 1 58 05 47 19
pleaseforward@exonhit.com
Sito Web :
www.exonhit.com

Presenza in Francia :

Dati principali 2008
Totale Equity fund dalla data di creazione –- (milioni di €) Totale sovvenzioni ricevute (milioni di €)
Responsabili
Direttore amministrativo:
Direttore R&D:

Presenza all’estero
ExonHit Therapeutics Inc. Avenel Business Park 217 Perry Parkway Gaithersburg, MD 20877
Tel: +1 (240) 683-7070 - Fax: +1 (240) 683-7060

Presentazione e/o prodotti
Drug discovey and diagnostics; a leader in the field of alternative RNA splicing. A strong
commercial position in the microarray disgnostics and drug market.


44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it
REGIONE NORD OUEST

8_
VIVALIS
6 rue Alain Bombard
44800 Saint Herblain Cedex
Nantes - France
Telefono
0033 2 38 07 37 10
0033 2 28 07 37 11
info@vivalis.com
Sito web :
www.vivalis.com

Dati principali 2008
Totale investimenti dalla data di creazione –Equity fund - (milioni di €) Totale sovvenzioni ricevute (milioni di €)
Responsabili
Presidente :
Franck Grimaud
Direttore R&D
Majid Methali

Presentazione e/o prodotti
Vivalis is a listed biopharmaceutical company that provides innovative cell-based solutions
for the industrial manufacture of viral vaccines and therapeutic proteins. It is also developing
vaccines and drugs for preventing and treating viral diseases.



44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it
REGIONE NORD -ESTE
9_
GENFIT
Parc Eurasanté
885 avenue Eugène Avinée
59120 Loos
Telefono :
0033 3 20 16 40 00
0033 3 20 16 40 06
contact@genfit.com
Sito web :
www.genfit.com

Dati principali 2008
Totale investimenti dalla data di creazione –Equity fund - (milioni di €) Totale sovvenzioni ricevute (milioni di €)
Responsabili
Direttore Generale :

Presenza all’estero
Genfit Corp. 245 First Street, 18 th floor – Cambridge MA 02142 (USA) – Phone + 1 (617) 444 84
16 – Fax +1 (617) 444 8405

Presentazione e/o prodotti
Genfit’s research efforts are focused on the discovey and development of new treatments in the growing therapeutis areas of cardiometabolic and neurodegenerative disosrders, such as prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity,and Alzeimer’s. 44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it

10_
TRANSGENE
Boulevard Gonthier d’Andernach
Parc Innovation –CS 801
67405 Illkirch-Graffenstaden Cedex
France

Presenza in Francia :

Telefono :
0033 3 88 27 91 00
0033 3 88 22 58 07
communication@transgene.fr
Sito web :
www.transgene.fr

Dati principali 2008
Totale investimenti dalla data di creazione –Equity fund - (milioni di €) Totale sovvenzioni ricevute (milioni di €)
Responsabili
Direttore generale:

Presenza all’estero
Transgene Inc. 5510 Nicholson Lane Kensington, Maryland 20895-1078 – USA
Prodotti
Vaccini terapeutici e prodotti di immunoterapie. 44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it
REGIONE RHONE-ALPES

11_
FLAMEL TECHNOLOGIES
33 avenue du Dr. Georges Levy
69693 Venissieux Cedex France

Presenza in Francia :
+1 stabilimento a Pessac (Francia)

Telefono :
0033 4 72 78 34 34
0033 4 72 78 34 35
info@flamel.com
Sito web :
www.flamel.com

Dati principali 2008
Totale investimenti dalla data di creazione –Equity fund - (milioni di €) Totale sovvenzioni ricevute (milioni di €)
Responsabili
Direttore :
Direttore produzione:

Presenza all’estero
USA, Nigel McWilliam (Director, Business Development) - E-mail: mcwilliam@flamel.com
Prodotti
Medusa®, a self-assembled poly-aminoacid nanoparticle system, is a versatile protein carrier for the
development of novel and second-generation long-acting native protein drugs. Medusa may also be applied
other large molecules, such as monoclonal antibody fragments and peptides. The Medusa® platform has many
advantages in that it enables the controlled delivery of fully-human, non-denatured proteins. We believe that this
will lead to a second-generation of protein-based drugs offering greater effectiveness and reduced toxicity and
44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it side-effects to patients. A microparticulate adaptation of Medusa has been developed that potentially can extend pharmacokinetics to two weeks or more, also without loss of bioactivity. The Micropump® platform enables the controlled delivery of small molecule drugs that are best absorbed in the
small intestine, a description that fits more than 70% of orally administered drugs. Unlike gastric-retention
tablets, the Micropump® platform is well suited for applications geared towards pediatric and geriatric patients.
That is because the Micropump® technology consists of the encapsulation of thousands of micro-particules,
each measuring 200-500 micrometers in diameter. These microparticles can be delivered in caplets but they can
also be delivered in suspensions or syrups. Because the active ingredients are entirely enclosed in each micro-
particle, Micropump® offers an additional advantage of taste masking.
12_
GENOWAY
181 Avenue Jean Jaurès
69007 Lyon - France
Telefono :
0033 4 37 65 41 00
info@genoway.com
Sito web :
www.genoway.com

Dati principali 2008
Totale investimenti dalla data di creazione –Equity fund - (milioni di €) Totale sovvenzioni ricevute (milioni di €)

Responsabili
Direttore :
Alexandre Fraichard

Prodotti
GenOway is a service provider dedicated to the development of genetically modified
mouse and rat models.
GenOway’s technology platform comprises technologies classically used in transgenesis such
a pronuclear microinjection, gene knock-out, knock-in and knock-down, together with
conditional and inducible systems and several innovative approaches.


44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it

REGIONE SUD-EST
13_
INNATE PHARMA - Sede
117, Avenue de Luminy – BP 30191
13009 Marseille - France
Telefono :
0033 4 30 30 30 87
0033 4 30 30 30 00
business@innate-pharma.com
Sito web :
www.innate-pharma.com

Dati principali 2008
Totale investimenti dalla data
di creazione –Equity fund - (milioni di €)
Totale sovvenzioni ricevute (milioni di €)
Responsabili
Direttore :
Hervé Braille
François

Presenza all’estero
Redmond, WA (USA), Sales office in Tokyo (Japan)

Prodotti
Therapeutic area, oncology, inflammation and oncology infections.


Bureau de Paris
44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it
14_
IPSOGEN - Sede
163 Avenue de Luminy
13009 Marseille 09 - France
Telefono :
0033 4 91 29 30 90
0033 4 91 29 30 99
infos@ipsogen.com
Sito web :
www.ipsogen.com

Dati principali 2008
Totale investimenti dalla data
di creazione –Equity fund - (milioni di €)
Totale sovvenzioni ricevute (milioni di €)
Responsabili
Direttore :
Vincent Fert

Presenza all’estero
Ipsogen Inc. Stamford – Connecticut (USA)
Prodotti
Leucemia and breast cancer products.


44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it
15_
NICOX
BP 313
06906 Sophia Antipolis Cedex France
Telefono :
0033 4 97 24 53 00
0033 4 97 24 53 09
nicox@nicox.com
Sito web :
www.nicox.com

Dati principali 2008
Totale investimenti dalla data
di creazione –Equity fund - (milioni di €)

Responsabili
Direttore :
Michele Garufi

Presenza all’estero
Nicox Research Institute Srl (Italia)
Nicox Inc. (Stati Uniti)
Prodotti
NicOx' most advanced investigational drug, naproxcinod, has successfully completed a clinical phase 3 program in patients with osteoarthritis of the knee and hip. Anti- inflammatory agents currently used in the treatment of osteoarthritis (traditional NSAIDs and COX-2 inhibitors) have long been associated with a range of side effects, including gastrointestinal problems. Furthermore, clinical findings continue to cast significant doubt on their cardiovascular safety, including their association with increased blood pressure. 44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it Naproxcinod is a unique nitric oxide-donating anti-inflammatory compound and the first- in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide Donator) in late-phase development. NicOx aims to demonstrate that naproxcinod is an anti-inflammatory agent with no detrimental effect on blood pressure and good gastrointestinal tolerability and NicOx has completed a clinical phase 3 program for naproxcinod in patients with OA of the knee (the 301 and 302 studies) and hip (the 303 study), with all three studies achieving highly statistically significant results on all three co-primary efficacy endpoints. NicOx submitted a New Drug Application (NDA) for naproxcinod to the US Food and Drug Administration (FDA) in September 2009. NicOx received a communication in November 2009 from the FDA stating that the NDA was accepted for filing. Based on the Prescription Drug User Fee Act (PDUFA), the FDA will complete its review 10 months after submission and has set an action date of July 24, 2010. The submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) is 44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it

Source: http://www.biotechinitaly.it/pdfUffici/Fiche15.pdf